Teva Pharmaceutical Industries and Sun Pharmaceutical Industries agreed to settle a patent-infringement lawsuit connected to Pfizer and Takeda Pharmaceutical's acid-reflux treatment Protonix for $2.15 billion. The two makers of generic drugs are accused of marketing a copy of an existing treatment with unexpired patents. "It is an important milestone, setting a 'book-end' case for the industry," said Bernstein Research analyst Aaron Gal. "It will serve to encourage patent settlements."
Published in Brief: